9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis

Kosmas, C.; Angel, J. H.; Athanasiou, A E; Rapti, Ageliki; Karanikas, Chrisanthi A.; Lambaki, Sofia; Politis, N.; Mylonakis, N.

doi:10.1016/s1359-6349(09)71801-4

Cited by 16 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipoplatin has received orphan drug status by the European Medicines Agency (EMA) for treatment of pancreatic adenocarcinoma [140]. Its efficacy has been subsequently demonstrated in various Phase II/III studies, such as NSCLC [141], HER2/neu negative metastatic breast cancer [142] and advanced gastric cancer [143]. In other human studies using Lipoplatin platinum accumulation in tumors and metastases was shown to be higher than that in adjacent normal tissue 20 h after i.v.…”

Section: Platinum Drug Delivery Using Nanocarriersmentioning

confidence: 99%

Nanocarriers for delivery of platinum anticancer drugs

Oberoi¹,

Nukolova²,

Kabanov³

et al. 2013

Advanced Drug Delivery Reviews

357

309

View full text Add to dashboard Cite

Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum–polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.

show abstract

Section: Platinum Drug Delivery Using Nanocarriersmentioning

confidence: 99%

Nanocarriers for delivery of platinum anticancer drugs

Oberoi¹,

Nukolova²,

Kabanov³

et al. 2013

Advanced Drug Delivery Reviews

357

309

View full text Add to dashboard Cite

show abstract

“…230 A safety profile more favourable than cisplatin was also observed, with particular regard to nephrotoxicity, neurotoxicity and asthenia. 230 Lipoplatin has also been studied with gemcitabine for malignant pleural mesothelioma, where a response was observed in one patient. and reduced occurrence of ototoxicity.…”

mentioning

confidence: 93%

The status of platinum anticancer drugs in the clinic and in clinical trials

et al. 2010

View full text Add to dashboard Cite

Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for\ud the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and\ud melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and\ud intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered\ud clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing\ud approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual\ud nations. During this time there have been more failures than successes with the development of 14 drugs\ud being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial\ud (satraplatin, picoplatin, LipoplatinTM and ProLindacTM). No new small molecule platinum drug has\ud entered clinical trials since 1999 which is representative of a shift in focus away from drug design and\ud towards drug delivery in the last decade. In this perspective article we update the status of platinum\ud anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued\ud during clinical trials, and discuss the results in the context of where we believe the field will develop over\ud the next decade

show abstract

“…All the 5 trials allocated patients to treatment arms randomly, but most of them did not report how the sequences were generated except that Stathopoulos et al [14] clarified their randomization was carried out according to the method of random permuted blocks within strata. Otherwise, 2 of the 5 trials were open-label [7,17] and 2 did not publish information on blinding, [13,18] while only one was conducted with evaluators blinded to treatment assignment. [14] Three trials showed evidence of incomplete outcomes’ data [13,17,18] and 2 trials with reporting biases had no information for key outcome data for interventions.…”

Section: Resultsmentioning

confidence: 99%

“…1). One phase III clinical trial has shown lipoplatin appeared more effective than conventional cisplatin and had a more favorable safety profile, particularly regarding nephrotoxicity, neurotoxicity and asthenia, [13] whereas another phase III clinical study has demonstrated liposomal cisplatin reduced nephrotoxicity but had a similar antitumor efficacy compared with conventional formulation. [14] There is an urgent need to conduct a meta-analysis addressing pertinent evidence to evaluate whether liposomal cisplatin could enhance antitumor efficacy over conventional nonliposomal cisplatin.…”

Section: Introductionmentioning

confidence: 99%